These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 36109464)

  • 1. Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination.
    Liu YM; Lee YL; Liu CE; Chen YC; Tien N; Su WC
    Infection; 2023 Apr; 51(2):531-534. PubMed ID: 36109464
    [No Abstract]   [Full Text] [Related]  

  • 2. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
    Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
    J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Estephan L; Lin YC; Lin YT; Chen YH; Pan SC; Hsieh SM; Torkehagen PF; Weng YJ; Cheng HY; Estrada JA; Waits A; Chen C; Lien CE
    Vaccine; 2023 May; 41(23):3497-3505. PubMed ID: 37080829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
    Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
    Shen X; Chalkias S; Feng J; Chen X; Zhou H; Marshall JC; Girard B; Tomassini JE; Aunins A; Das R; Montefiori DC
    N Engl J Med; 2022 Sep; 387(13):1234-1236. PubMed ID: 36083119
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.
    Chen CJ; Yang LY; Chang WY; Huang YC; Chiu CH; Shih SR; Huang CG; Huang KA
    Nat Commun; 2022 Sep; 13(1):5466. PubMed ID: 36115850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk reduction analysis of mix-and-match vaccination strategy in healthcare workers during SARS-CoV-2 Omicron variant predominant period: A multi-center cohort study in Taiwan.
    Chen YC; Chuang CH; Shen TF; Lin CS; Yang HP; Li HC; Chen CL; Lin IF; Chiu CH
    Hum Vaccin Immunother; 2023 Aug; 19(2):2237387. PubMed ID: 37534447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning of humoral immunity depending on the types of COVID-19 vaccine.
    Lim SY; Kim JY; Jung J; Yun SC; Kim SH
    Infect Dis (Lond); 2023 Mar; 55(3):216-220. PubMed ID: 36625442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing humoral immunity and CD4
    Shen CF; Fu YC; Ho TS; Chen PL; Lee NY; Tsai BY; Tsai PJ; Ko WC; Liu CC; Cheng CM; Shieh CC
    Clin Immunol; 2023 Jun; 251():109342. PubMed ID: 37100338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
    Huang ST; Huang YS; Liu WD; Pan SC; Sun HY; Lien CE; Chen C; Hsieh SM
    J Formos Med Assoc; 2023 Nov; 122(11):1165-1173. PubMed ID: 37321955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5.
    Tseng HF; Ackerson BK; Bruxvoort KJ; Sy LS; Tubert JE; Lee GS; Ku JH; Florea A; Luo Y; Qiu S; Choi SK; Takhar HS; Aragones M; Paila YD; Chavers S; Talarico CA; Qian L
    Nat Commun; 2023 Jan; 14(1):189. PubMed ID: 36635284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study.
    Kohmer N; Stein S; Schenk B; Grikscheit K; Metzler M; Rabenau HF; Widera M; Herrmann E; Wicker S; Ciesek S
    Int J Infect Dis; 2023 Mar; 128():166-175. PubMed ID: 36587839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
    Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
    EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.